Development of dna vaccine targeting e6 and e7 proteins of human papillomavirus 16 (Hpv16) and hpv18 for immunotherapy in combination with recombinant vaccinia boost and pd-1 antibody

Shiwen Peng, Louise Ferrall, Stephanie Gaillard, Chenguang Wang, Wei Yu Chi, Chuan Hsiang Huang, Richard B.S. Roden, T. C. Wu, Yung Nien Chang, Chien Fu Hung

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Immunotherapy for cervical cancer should target high-risk human papil-lomavirus types 16 and 18, which cause 50% and 20% of cervical cancers, respec-tively. Here, we describe the construction and characterization of the pBI-11 DNA vaccine via the addition of codon-optimized human papillomavirus 18 (HPV18) E7 and HPV16 and 18 E6 genes to the HPV16 E7-targeted DNA vaccine pNGVL4a-SigE7 (detox)HSP70 (DNA vaccine pBI-1). Codon optimization of the HPV16/18 E6/E7 genes in pBI-11 improved fusion protein expression compared to that in DNA vaccine pBI-10.1 that utilized the native viral sequences fused 3' to a signal sequence and 5' to the HSP70 gene of Mycobacterium tuberculosis. Intramuscular vaccination of mice with pBI-11 DNA better induced HPV antigen-specific CD8+ T cell immune responses than pBI-10.1 DNA. Furthermore, intramuscular vaccination with pBI-11 DNA generated stronger therapeutic responses for C57BL/6 mice bearing HPV16 E6/E7-express-ing TC-1 tumors. The HPV16/18 antigen-specific T cell-mediated immune responses generated by pBI-11 DNA vaccination were further enhanced by boosting with tis-sue-antigen HPV vaccine (TA-HPV). Combination of the pBI-11 DNA and TA-HPV boost vaccination with PD-1 antibody blockade significantly improved the control of TC-1 tumors and extended the survival of the mice. Finally, repeat vaccination with clinical-grade pBI-11 with or without clinical-grade TA-HPV was well tolerated in vaccinated mice. These preclinical studies suggest that the pBI-11 DNA vaccine may be used with TA-HPV in a heterologous prime-boost strategy to enhance HPV 16/18 E6/ E7-specific CD8+ T cell responses, either alone or in combination with immune checkpoint blockade, to control HPV16/18-associated tumors. Our data serve as an important foundation for future clinical translation. IMPORTANCE Persistent expression of high-risk human papillomavirus (HPV) E6 and E7 is an obligate driver for several human malignancies, including cervical cancer, wherein HPV16 and HPV18 are the most common types. PD-1 antibody immunother-apy helps a subset of cervical cancer patients, and its efficacy might be improved by combination with active vaccination against E6 and/or E7. For patients with HPV16+ cervical intraepithelial neoplasia grade 2/3 (CIN2/3), the precursor of cervical cancer, intramuscular vaccination with a DNA vaccine targeting HPV16 E7 and then a recombi-nant vaccinia virus expressing HPV16/18 E6-E7 fusion proteins (TA-HPV) was safe, and half of the patients cleared their lesions in a small study (NCT00788164). Here, we sought to improve upon this therapeutic approach by developing a new DNA vaccine that targets E6 and E7 of HPV16 and HPV18 for administration prior to a TA-HPV booster vaccination and for application against cervical cancer in combination with a PD-1-blocking antibody.

Original languageEnglish (US)
Article numbere03224-20
Pages (from-to)1-19
Number of pages19
Issue number1
StatePublished - Jan 1 2021


  • DNA vaccine
  • E6
  • E7
  • HPV-associated cancer
  • HPV16
  • HPV18
  • Human papillomavirus
  • PD-1
  • TA-HPV

ASJC Scopus subject areas

  • Microbiology
  • Virology


Dive into the research topics of 'Development of dna vaccine targeting e6 and e7 proteins of human papillomavirus 16 (Hpv16) and hpv18 for immunotherapy in combination with recombinant vaccinia boost and pd-1 antibody'. Together they form a unique fingerprint.

Cite this